TMC Life Research, Inc.
Welcome,         Profile    Billing    Logout  
 4 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Miller, Charles E
NCT05394662: Safety and Effectiveness of Juveena™ Hydrogel System Following TCGP At High-Risk for Intrauterine Adhesions

Recruiting
3
150
US
Juveena Hydrogel System
Rejoni Inc.
Intrauterine Adhesion
03/25
03/25
BRUNELLO, NCT06571045: A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Recruiting
2/3
960
Europe, US, RoW
Ranibizumab, Lucentis, EYE103, Restoret
EyeBiotech Ltd.
Diabetic Macular Edema (DME)
12/27
12/27
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
TITAN:SvS, NCT03536312: Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

Recruiting
N/A
610
Canada, US
Thoracic Aortic Surgery
Ottawa Heart Institute Research Corporation, University of Calgary
Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm
05/25
05/26
Jacobs, Mark
NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Recruiting
4
1710
US
LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet
Insud Pharma, Chemo Research
Change in Bone Mineral Density, Bone Loss
07/26
03/27
NCT05461573: Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

Active, not recruiting
3
1009
US
Drospirenone, LPRI-CF113
Insud Pharma, Chemo Research
Contraception, Change in Bone Mineral Density
05/24
05/25
NCT05399641: Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Completed
3
150
US
Ibrexafungerp
Scynexis, Inc.
Vulvovaginal Candidiasis
05/23
08/23
SIS, NCT06597344: A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

Recruiting
3
90
US
Gepotidacin
GlaxoSmithKline
Urinary Tract Infections
03/25
03/25
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
Foye, Kelsey
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
Walton, Marie
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
GBT021601-021, NCT05431088: A Phase 2/3 Study in Adult and Pediatric Participants With SCD

Active, not recruiting
2/3
429
Europe, US, RoW
Osivelotor, PF-07940367 or GBT021601
Pfizer, Pfizer
Sickle Cell Disease
10/28
10/28
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
Rodriguez, Alison
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25

Download Options